Von hippel-lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6449-6455

  Aune, Gregory J ^a   Takagi, Kazutaka ^a   Sordet, Olivier ^a   JoseeGuirouilh Barbat ^a   Antony, Smitha ^a   Bohr, Vilhelma ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; RNA POLYMERASE II; TRABECTEDIN; VON HIPPEL LINDAU PROTEIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; DNA BINDING PROTEIN; ERCC2 PROTEIN, HUMAN; ERCC6 PROTEIN, HUMAN; HELICASE; LEUPEPTIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VHL PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XPC PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EXCISION REPAIR; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RNA DEGRADATION; CELL CULTURE; CELL SURVIVAL; COCKAYNE SYNDROME; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; ENZYMOLOGY; GENETIC COMPLEMENTATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; SARCOMA; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING; XERODERMA PIGMENTOSUM;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; COCKAYNE SYNDROME; CYSTEINE PROTEINASE INHIBITORS; DIOXOLES; DNA DAMAGE; DNA HELICASES; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FIBROBLASTS; GENETIC COMPLEMENTATION TEST; HUMANS; LEUPEPTINS; NEOPLASMS; PHOSPHORYLATION; RNA POLYMERASE II; SARCOMA; TETRAHYDROISOQUINOLINES; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XERODERMA PIGMENTOSUM; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 58149200507     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0730     Document Type: Article

References (50)

1. Pommier Y, Cherfils J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol Sci 2005;28:136-45.
2. Rinehart KL, Holt TG, Fregeau NL, et al. Bioactive compounds from aquatic and terrestrial sources. J Nat Prod 1990;53:771-92.
3. GuanY, Sakai R, Rinehart KL, Wang AH. Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993;10:793-818.
4. Izbicka E, Lawrence R, Raymond E, et al. In vitro anti-tumor activity of the novel marine agent, ecteinasci-din-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-7.
5. Sakai R, Rinehart KL, Guan Y, Wang AH. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc Natl Acad Sci USA1992;89:11456-60.
6. Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinasci-din-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res1998;4:1977-83.
7. Aune GJ, Furuta T, Pommier Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 2002;13:545-55.
8. D'Incalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist 2002;7:210-6.
9. Fayette J, Coquard IR, Alberti L,etal. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18:347-53.
10. Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000;97:6775-9.
11. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000;97:6780-4.
12. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001;7:584-90.
13. Martinez EJ, Corey EJ, Owa T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8: 1151-60.
14. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-81.
15. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry1996;35:13303-9.
16. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
17. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
18. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer2001;92:583-8.
19. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH.The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001;8:1033-49.
20. de Laat WL, Jaspers NGJ, Hoeijmakers JHJ. Molecular mechanisms of nucleotide excision repair. Genes Dev1999;13:768-85.
21. Sancar A, Lindsey-Boltz LA, Unsal-KaccmazK,Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem2004;73:39-85.
22. Ribar B, Prakash L, Prakash S. ELA1 and CUL3 are required along with ELC1 for RNA polymerase II poly-ubiquitylation and degradation in DNA-damaged yeast cells. Mol Cell Biol 2007;27:3211-6.
23. Svejstrup JQ. Contending with transcriptional arrest during RNAPII transcript elongation. Trends Biochem Sci 2007;32:165-71.
24. Cline SD, Hanawalt PC. Who's on first in the cellular response to DNA damage? Nat Rev Mol Cell Biol 2003;4:361-72.
25. Reardon JT, Sancar A. Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 2005;79:183-235.
26. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-62.
27. Selzer RR, Nyaga S,Tuo J, et al. Differential requirement for the AT Pase domain of the Cockayne syndrome group B gene in the processing of UV-induced DNA damage and 8-oxoguanine lesions in human cells. Nucleic Acids Res 2002;30:782-93.
28. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-12.
29. Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 2006;20:2922-36.
30. Corden JL. Transcription. Seven ups the code. Science 2007;318:1735-6.
31. Chapman RD, Heidemann M, Albert TK, et al. Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. Science 2007;318:1780-2.
32. Zhang J, Corden JL. Phosphorylation causes a con-formational change in the carboxyl-terminal domain of the mouse RNA polymerase II largest subunit. J Biol Chem1991;266:2297-302.
33. Saunders A, Core LJ, Lis JT. Breaking barriers to transcription elongation. Nat Rev Mol Cell Biol 2006; 7:557-67.
34. Dubois MF, Bellier S, Seo SJ, Bensaude O. Phosphorylation of the RNA polymerase II largest subunit during heat shock and inhibition of transcription in He La cells. J Cell Physiol 1994;158:417-26.
35. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002;8:3893-903.
36. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-11.
37. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7:3251-7.
38. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
39. Kuznetsova AV, Meller J, Schnell PO, et al. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 2003;100:2706-11.
40. Na X, Duan HO, Messing EM, et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 2003; 22:4249-59.
41. Zewail-Foote M, Hurley LH. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites. J Am Chem Soc 2001;123: 6485-95.
42. Brueckner F, Hennecke U, Carell T, Cramer P. CPD damage recognition by transcribing RNA polymerase II. Science 2007;315:859-62.
43. Bregman DB, Halaban R, van Gool AJ, Henning KA, Friedberg EC, Warren SL. UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells. Proc Natl Acad Sci USA 1996;93:11586-90.
44. Ratner JN, Balasubramanian B, Corden J, Warren SL, Bregman DB. Ultraviolet radiation-induced ubiquitination and proteasomal degradation of the large subunit of RNA polymerase II. Implications for transcription-coupled DNA repair. J Biol Chem1998;273: 5184-9.
45. Inukai N, Yamaguchi Y, Kuraoka I, et al. A novel hydrogen peroxide-induced phosphorylation and ubiquitination pathway leading to RNA polymerase II proteolysis. J Biol Chem2004;279:8190-5.
46. KimWY,Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
47. Frew I J, Krek W. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 2007;19:685-90.
48. Mellon I, Bohr VA, Smith CA, Hanawalt PC. Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci USA 1986;83:8878-82.
49. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902.
50. Kohn KW, Aladjem MI, Kim S, Weinstein JN, Pommier Y. Depicting combinatorial complexity with the molecular interaction map notation. Mol Syst Biol 2006;2:51.